Condition (MeSH)
Fungemia
ClinicalTrials.gov lists 90 trials for Fungemia or a narrower condition beneath it. Pfizer has the most among industry and government lead sponsors, with 15.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
29 of the 90 trials are tagged with Fungemia itself; the rest are tagged with a narrower condition beneath it.
When did Fungemia trials start? (25)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 11
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 2 |
| 2024 | 3 |
| 2022 | 3 |
| 2020 | 1 |
| 2019 | 3 |
| 2018 | 4 |
| 2017 | 3 |
| 2016 | 3 |
| 2015 | 1 |
Showing 10 of 25 earlier years.
No forecast is made for this condition: it averages 2.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Fungemia trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 5 |
| Phase 1/2 | 1 |
| Phase 2 | 9 |
| Phase 3 | 24 |
| Phase 4 | 10 |
| Not applicable | 8 |
| Observational | 33 |
How many Fungemia trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 3 |
| Recruiting | 3 |
| Completed | 63 |
| Terminated | 8 |
| Withdrawn | 3 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Fungemia trials? (11)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Pfizer | 15 |
| Astellas Pharma Inc | 8 |
| National Cancer Institute (NCI) | 5 |
| Basilea Pharmaceutica | 3 |
| Scynexis, Inc. | 3 |
Showing 5 of 11 sponsors.
Which drugs are being tested for Fungemia? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Anidulafungin | 9 |
| APX001 | 3 |
| IBREXAFUNGERP | 3 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Fluconazol | 14 |
| Comparator: Micafungin sodium | 14 |
| MK0991, caspofungin acetate | 9 |
| Voriconazole 1% | 8 |
| Active Anidulafungin | 2 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Fungemia trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Septic shock | 113 | 15 |
| Sepsis | 68 | 10 |
| Respiratory failure | 55 | 13 |
| SEPSIS | 45 | 1 |
| Pneumonia | 37 | 12 |
Showing 5 of 10 adverse events.
Which publications cover Fungemia? (73)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Evaluation of the ePlex Blood Culture Identification Panels for Detection of Pathogens in Bloodstream Infections. | Journal of clinical microbiology | 2019 | Yes |
| Cost-effectiveness analysis of chlorhexidine-alcohol versus povidone iodine-alcohol solution in the prevention of intravascular-catheter-related bloodstream infections in France. | PloS one | 2018 | Yes |
| The Effect of Molecular Rapid Diagnostic Testing on Clinical Outcomes in Bloodstream Infections: A Systematic Review and Meta-analysis. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2017 | Yes |
| Fatal course of Saprochaete capitata fungemia in children with acute lymphoblastic leukemia. | Pediatric hematology and oncology | 2017 | Yes |
| Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease. | The Journal of antimicrobial chemotherapy | 2016 | Yes |
Showing 5 of 73 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.